公开(公告)号：US12139524B2

公开(公告)日：2024-11-12

申请号：US17557607

申请日：2021-12-21

Applicant: Memorial Sloan Kettering Cancer Center

Inventor： Prasad S. Adusumilli ,  Michel Sadelain

IPC: A61K35/17 ,  A61K35/28 ,  A61K38/00 ,  A61K38/17 ,  A61K38/19 ,  A61K38/20 ,  A61K38/48 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/64

Abstract: Disclosed herein are cells that are immune cells or precursor cells thereof, which cells recombinantly express a chimeric antigen receptor (CAR), and a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, wherein the CAR binds to a cancer antigen. Also disclosed herein are T cells that recognize and are sensitized to a cancer antigen, which T cells recombinantly express a dominant negative form of an inhibitor of a T cell-mediated immune response. Additionally provided are methods of using such cells to treat cancer in a subject in need thereof.

公开(公告)号：US20240360068A1

公开(公告)日：2024-10-31

申请号：US18770018

申请日：2024-07-11

Applicant: Francis Johnson ,  Lorne Golub

Inventor： Francis Johnson ,  Lorne Golub

IPC: C07C69/738 ,  C07C49/255 ,  C07C225/22 ,  C07C235/78 ,  C07C235/80 ,  C07C237/20 ,  C07D213/50 ,  C12N9/64

CPC classification number: C07C69/738 ,  C07C49/255 ,  C07C225/22 ,  C07C235/78 ,  C07C235/80 ,  C07C237/20 ,  C07D213/50 ,  C12N9/6491 ,  C12Y304/24

Abstract: This invention provides a compound having the structure




wherein α, β, X, Y, and R1-R11 are defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NFκ-B activation in a population of cells.

公开(公告)号：US20240349734A1

公开(公告)日：2024-10-24

申请号：US18683618

申请日：2022-08-23

Applicant: KAO CORPORATION

Inventor： Takahiro HIOKI ,  Saki TAKAHIRA ,  Akihito KAWAHARA

IPC: A01N63/50 ,  C12N9/64

CPC classification number: A01N63/50 ,  C12N9/6489 ,  C12Y304/24032

Abstract: Provided are a rigid surface treatment agent capable of imparting an antibacterial property to a rigid surface, and a method for treating a rigid surface using the rigid surface treatment agent. The rigid surface treatment agent comprises, as an active component, a polypeptide which consists of an amino acid sequence of SEQ ID NO: 2, or a polypeptide which consists of an amino acid sequence having an identity of at least 80% with the amino acid sequence of SEQ ID NO: 2, and has activity of degrading a glycine-glycine bond in a peptide sequence.

公开(公告)号：US12104188B2

公开(公告)日：2024-10-01

申请号：US17716253

申请日：2022-04-08

Applicant: Allogene Therapeutics, Inc.

Inventor： Meritxell Galindo Casas ,  Thomas John Van Blarcom

IPC: C12N9/64 ,  A61K31/7088 ,  A61K35/17 ,  A61K38/48 ,  A61K38/52 ,  C12N5/0783 ,  C12N9/90 ,  C12N11/18

CPC classification number: C12N9/6472 ,  A61K31/7088 ,  A61K35/17 ,  A61K38/4873 ,  A61K38/52 ,  C12N5/0636 ,  C12N9/90 ,  C12N11/18 ,  C12Y304/22062 ,  C12Y502/01008 ,  C07K2319/50 ,  C07K2319/70 ,  C12N2501/734 ,  C12N2510/00 ,  C12N2740/16043

Abstract: Provided herein are modified caspase-9 polypeptides, and chimeric caspase-9 proteins containing the modified caspase-9 polypeptides. The disclosure further provides polynucleotides encoding these proteins, engineered host cells containing these polynucleotides and proteins, including host cells that co-express a chimeric antigen receptor, and methods of making and using the same.

公开(公告)号：US20240307536A1

公开(公告)日：2024-09-19

申请号：US18271883

申请日：2022-01-11

Applicant: Hadasit Medical Research Services and Development Ltd.

Inventor： Amnon PELED ,  Inbal MISHALIAN

IPC: A61K39/00 ,  A61P35/02 ,  C07K14/54 ,  C07K14/55 ,  C07K14/705 ,  C07K14/715 ,  C07K16/28 ,  C12N5/0783 ,  C12N9/64

CPC classification number: A61K39/4611 ,  A61K39/4631 ,  A61K39/4635 ,  A61K39/464402 ,  A61K39/464412 ,  A61P35/02 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/7056 ,  C07K14/7158 ,  C07K16/2803 ,  C07K16/2866 ,  C12N5/0638 ,  C12N9/6467 ,  C12Y304/21079 ,  A61K2239/26 ,  A61K2239/48 ,  C07K2317/622 ,  C07K2317/73 ,  C12N2501/2302 ,  C12N2501/515 ,  C12N2510/00

Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides improved cell compositions and methods for adoptive cell therapy, useful in the treatment of cancer. More specifically, embodiments of the invention employ the use of cell compositions comprising a high proportion of activated cytotoxic CD8+ cells and in particular CD8+NKG2D+granzyme-B+ cells characterized by enhanced cytotoxicity, to processes for their preparation from peripheral blood mononuclear cells (PBMC), and to their use in cancer management.

公开(公告)号：US20240299510A1

公开(公告)日：2024-09-12

申请号：US18270436

申请日：2021-12-31

Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services

Inventor： Peter D. Kwong ,  Gwo-Yu Chuang ,  Baoshan Zhang ,  Wing-Pui Kong ,  Yiran Wang ,  Cara Chao ,  John R. Mascola ,  Li Ou ,  Tongqing Zhou ,  Yongping Yang ,  Bohan Liu ,  Cheng Cheng ,  Daniel W. Biner ,  Reda Rawi

IPC: A61K39/00 ,  A61K45/06 ,  A61P3/06 ,  C12N9/64

CPC classification number: A61K39/0005 ,  A61K45/06 ,  A61P3/06 ,  C12N9/6454 ,  C12Y304/21061

Abstract: The present disclosure describes the grafting of epitope residues from human PCSK9 to non-human PCSK9 or PCSK9 structural homologs and elimination of 9-mers oligopeptides that are found in human protein to reduce self-targeting response. Anti-genicity of the epitope-scaffold constructs was demonstrated toward anti-human PCSK9 antibodies. similar to wild type human PCSK9. It was shown that disclosed PCSK9 immunogens could significantly reduce LDL and cholesterol levels in immunized mice.

公开(公告)号：US12084696B2

公开(公告)日：2024-09-10

申请号：US18501966

申请日：2023-11-03

Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Inventor： Henry M. Colecraft ,  Scott Kanner

IPC: C12N9/64 ,  A61K38/00 ,  C12N15/85 ,  C12Q1/6883

CPC classification number: C12N9/6472 ,  C12N15/85 ,  C12Q1/6883 ,  C12Y304/22 ,  A61K38/00 ,  C12Q2600/156

Abstract: The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

公开(公告)号：US20240294602A1

公开(公告)日：2024-09-05

申请号：US18647837

申请日：2024-04-26

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  A01N37/46 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/64 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/566 ,  G01N33/569

CPC classification number: C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/04 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US12071456B2

公开(公告)日：2024-08-27

申请号：US17150426

申请日：2021-01-15

Applicant: AMUNIX PHARMACEUTICALS, INC.

Inventor： Volker Schellenberger ,  Joshua Silverman ,  Chia-wei Wang ,  Benjamin Spink ,  Willem P. Stemmer ,  Nathan Geething ,  Wayne To ,  Jeffrey L. Cleland

IPC: C07K14/47 ,  C07K14/00 ,  C07K14/545 ,  C07K14/605 ,  C07K14/61 ,  C07K14/745 ,  C12N9/64

CPC classification number: C07K14/47 ,  C07K14/001 ,  C07K14/545 ,  C07K14/605 ,  C07K14/61 ,  C07K14/745 ,  C12N9/6437 ,  C12N9/644 ,  C07K2319/31 ,  C07K2319/35

Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.

公开(公告)号：US12050218B2

公开(公告)日：2024-07-30

申请号：US16476961

申请日：2018-01-12

Applicant: NUtech Ventures

Inventor： Srivatsan Kidambi ,  Oleh Khalimonchuk

IPC: G01N31/00 ,  C07K16/30 ,  C12N9/64 ,  G01N33/53 ,  G01N33/574

CPC classification number: G01N33/57415 ,  C07K16/3015 ,  C12N9/6489 ,  G01N33/57484 ,  G01N2333/8146

Abstract: The use of mitochondrial protease OMA1 as a theranostic marker for breast cancer, tumor progression, metastatis and drug responsiveness is disclosed herein.